Classical Hodgkin Lymphoma
Conditions
Keywords
Hodgkin, Elderly patients, CGA
Brief summary
The aim of the study is to develop a prognostic index for elderly patients with newly diagnosed cHL starting from a prospective observational study of consecutive cases registered after the completion of the Comprehensive Geriatric Assessment (CGA)
Detailed description
The aim of the study is to develop a prognostic index for elderly patients with newly diagnosed cHL starting from a prospective observational study of consecutive cases registered after the completion of the Comprehensive Geriatric Assessment (CGA) Prospective data collection study of a consecutive series of newly diagnosed elderly cHL patients undergoing CGA before any therapy with the use of ADL, IADL and CIRS-G. Patients who will be considered not eligible to receive treatment or to be given only palliative therapy after CGA assessment are eligible for the study. Patients will be screened and restaged according to clinical practice instrumental and laboratory assessments timing and type of examinations.
Interventions
OTHERTreatment for clinical practise
Prospective data collection with the aim to to develop a prognostic index for elderly patients with newly diagnosed cHL
Sponsors
Fondazione Italiana Linfomi - ETS
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of classical Hodgkin Lymphoma 2. Age ≥ 65 year 3. Evaluation of Comprehensive Geriatric Assessment at baseline 4. Signed informed consent 5. Previously untreated patients
Exclusion criteria
None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OS | June 2018-December 2025 (7.5 years) | Overall survival (OS). From the date of diagnosis to the date of last observation or death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | June 2018-December 2025 (7.5 years) | Progression Free Survival (PFS): From the date of diagnosis to the last follow-up, or to one of the following events: disease progression during treatment, or relapse, or death from any cause. |
| FFS | June 2018-December 2025 (7.5 years) | Failure Free Survival (FFS). From the date of diagnosis to to any treatment failure including disease progression, or discontinuation of treatment for any reason, (eg, disease progression, toxicity, patient preference, initiation of new treatment), or death from any cause. |
| Response initial therapy | June 2018-January 2024 (5.5 years, 6-7 month after the enrolment) | Response initial therapy: Rate of complete remission (CR) after chemotherapy +/-RT, according to Cheson 2007 |
Countries
Italy
Contacts
Primary ContactVittorio Ruggero Zilioli, MD
Outcome results
None listed